



Management of *P. acnes* bone and joint infection in a regional reference centre in France

C. Chassin, F. Valour, J. Saison, M.H. Fessy, F. Laurent, F. Ader, S. Lustig, C. Chidiac, T. Ferry on behalf of the Lyon BJI Study group

Hospices Civils de Lyon, France, Université Claude Bernard 1 Lyon, France, Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France

Introduction

Despite *P. acnes* is a frequent pathogen involved in bone and joint infection (BJI), few data are available in the literature on P. acnes BJI management and outcome.

Materiel and methods

We performed a retrospective cohort study (2007-2013) adult patients presenting postoperative including monomicrobial P. acnes BJI (at least 2 peroperative samples were required for the diagnosis) in a regional reference center in France. Clinical data were collected and determinants for treatment success were determined using univariate Cox analysis.



Forty-one patients were included during the period (figure 1). Clinical characteristics are detailed in the table 1.



Figure 1. Flow chart and outcomes of the 41 patients with *P. acnes* infection

	Success	Failure	Total	n
	(n=31)	(n=9)	(n=40)	Р
Symptoms:				
Fever	5 (16.1%)	2 (22.2%)	7 (17.5%)	NS
Pain	30 (96.8%)	9 (100%)	39 (97.5%)	NS
Local inflammation	18 (58.1%)	7 (77.8%)	25 (62.5%)	NS
Sinus tract	5 (16.1%)	4 (44.4%)	9 (22.5%)	NS
Abscess	11 (35.5%)	4 (44.4%)	15 (37.5%)	NS
CRP max (mg/L), mean	104	88	100	NS
No of positive intraoperative	26(+0.40)	4 (+0 57)	2 6 (+0.2)	NC
samples, mean	5.0 (±0.40)	4 (±0.57)	5.0 (±0.5)	145
No of intraoperative samples,	4.0 (10.2()	5 (10 (2)	4.0 (10.2)	NC
mean	4.9 (±0.36)	5 (IU.02)	4.9 (±0.3)	NS
Infection classification:				
Acute (<1month)	3 (9.7%)	0	3 (7.5%)	NS
Subacute (1-3months)	4 (12.9%)	3 (33.3%)	7 (17.5%)	NS
Delayed (3-12months)	14 (45.2%)	6 (66.7%)	20 (50%)	NS
Late (>12months)	10 (32.3%)	0	10 (25%)	NS
BJI> 3months	24 (77.4%)	6 (66.7%)	30 (75%)	NS
Comparisons between groups were not significant				

arisons between groups were not significal

Table 2. Characteristics of the 40 patients (1 patient lost to follow-up was excluded)

Using univariate Cox analysis and Kaplan Meier curves, we found as determinants for treatment success the two following factors: optimal surgical treatment (HR 0.260; CI95% 0.070-0.974; p=0.046; figure 2) and the prescription of immediate empirical antimicrobial therapy (HR 0.101; Cl95% 0.019-0.525; p=0.006) (figure 3). No other between group differences were observed.



Figure 2. Kaplan Meier survival curves for patients for who optimal or nondoptimal surgery



Not optimal surger

Log-Rank p =0.0031



Figure 3. Kaplan Meier curves for patients receiving or not an immediate post operative antimicrobial therapy

Conclusion

P. acnes is mainly responsible for late implant-associated BJI. Prescription of immediate post-operative antimicrobial therapy seems to influence the outcome. As P. acnes is usually not considered as virulent as other pathogen such as staphylococci, the surgical strategy is often conservative, leading to treatment failure. Chronic implant-associated P. acnes BJI required aggressive surgical management that facilitate the cure and could help to reduce the duration of antibiotic therapy.

Lyon BJI Study group

Physicians – Tristan Ferry, Thomas Perpoint, André Boibieux, François Biron, Florence Ader, Julien Saison, Florent Valour, Fatiha Daoud, Johanna Lippman, Evelyne Braun, Marie-Paule Vallat, Patrick Miailhes, Christian Chidiac, Dominique Peyramond; Surgeons – Sébastien Lustig, Philippe Neyret, Olivier Reynaud, Caroline Debette, Adrien Peltier, Anthony Viste, Jean-Baptiste Bérard, Frédéric Dalat, Olivier Cantin, Romain Desmarchelier, Thibault Vermersch, Michel-Henry Fessy, Cédric Barrey, Francesco Signorelli, Emmanuel Jouanneau, Timothée Jacquesson, Pierre Breton, Ali Mojallal, Fabien Boucher, Hristo Shipkov; Microbiologists – Frederic Laurent, François Vandenesch, Jean-Philippe Rasigade, Céline Dupieux; Nuclear Medicine – Isabelle Morelec, Marc Janier, Francesco Giammarile; PK/PD specialists – Michel Tod, Marie-Claude Gagnieu, *Sylvain Goutelle;* Clinical Research Assistant – *Eugénie Mabrut*